Asset
DINUTUXIMAB
United Therapeutics Corporation Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03098030 | phase2_3 | completed | 2017-06-01 | 2020-01-27 | United Therapeutics | Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer |
| NCT01592045 | phase1_2 | completed | 2012-08-01 | 2014-06-01 | United Therapeutics | ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| BLA 125516 | BLA | United Therapeutics Corporation |
Marketed products (1)
- UNITUXIN